Furthermore, our work has established for the first time that sunitinib-induced upregulation of PAK1 kinase activity and ensuing NF-κB/IL-6 activation contributed to the accumulation of stem-like cancer cells, RCC progression and sunitinib resistance. The gene discussed is IL6; the disease is renal cell carcinoma.